**Amendments to the Claims:** 

This listing of claims will replace all prior versions, and listings, of claims in the

application:

**Listing of Claims:** 

Claim 1 (currently amended): A Steptococcus pneumoniae protein or polypeptide having

a sequence selected from those shown in table Table 2.

Claim 2 (currently amended): A Steptococcus pneumoniae protein or polypeptide having

a sequence selected from those shown in table Table 4.

Claim 3 (previously presented): A protein or polypeptide as claimed in claim 1 or claim 2

provided in substantially pure form.

Claim 4 (previously presented): A protein or polypeptide which is substantially identical

to one defined in any of claims 1 to 3.

Claim 5 (previously presented): A homologue or derivative of a protein or polypeptide as

defined in any one of claims 1 to 4.

Claim 6 (previously presented): An antigenic and/or immunogenic fragment of a protein

or polypeptide as defined in Tables 2-4.

Claim 7 (currently amended): A nucleic acid molecule comprising or consisting of a

sequence which is:

(i) any of the DNA sequences set out in Table 1 or their RNA equivalents;

(ii) a sequence which is complementary to any of the sequences of (i);

(iii) a sequence which codes for the same protein or polypeptide, as those sequences of

(i) or (ii);

(iv) a sequence which is substantially identical with any of those of (i), (ii) and (iii);

3

APPLICATION No.: 09/769,787 AMDT. DATED: DECEMBER 12, 2003

REPLY TO OFFICE ACTION OF JULY 17, 2003

(v) a sequence which codes for a homologue, derivative or fragment of a protein defined in Table 1.

Claim 8 (currently amended): A nucleic acid molecule comprising or consisting of a sequence which is:

- (i) any of the DNA sequences set out in Table 4 or their RNA equivalents;
- (ii) a sequence which is complementary to any of the sequences of (i);
- (iii) a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);
  - (iv) a sequence which is substantially identical with any of those of (i), (ii) and (iii);
- (v) a sequence which codes for a homologue, derivative or fragment of a protein as defined in Table 4.

Claim 9 (previously presented): The use of a protein or polypeptide having a sequence selected from those shown in Tables 2-4, or homologues, derivatives and/or fragments thereof, as an immunogen and/or antigen.

Claim 10 (previously presented): An immunogenic and/or antigenic composition comprising one or more proteins or polypeptides selected from those whose sequences are shown in Tables 2-4, or homologues or derivatives thereof, and/or fragments of any of these.

Claim 11 (previously presented): An immunogenic and/or antigenic composition as claimed in claim 10 which is a vaccine or is for use in a diagnostic assay.

Claim 12 (previously presented): A vaccine as claimed in claim 11 which comprises one or more additional components selected from excipients, diluents, adjuvants or the like.

Claim 13 (previously presented): A vaccine composition comprising one or more nucleic acid sequences defined in Tables 1, 3, or 4.

Claim 14 (previously presented): A method for the detection/diagnosis of *S. pneumoniae* which comprises the step of bringing into contact a sample to be tested with at least one protein or polypeptide as defined in Tables 2-4, or homologue, derivative or fragment thereof.

APPLICATION No.: 09/769,787 AMDT. DATED: DECEMBER 12, 2003

REPLY TO OFFICE ACTION OF JULY 17, 2003

Claim 15 (previously presented): An antibody capable of binding to a protein or polypeptide as defined in tables 2-4, or for a homologue, derivative or fragment thereof.

Claim 16 (previously presented): An antibody as defined in claim 15 which is a monoclonal antibody.

Claim 17 (currently amended): A method for the detection/diagnosis of *S. pneumoniae* which comprises the step of bringing into contact a sample to be tested and at least one antibody as defined din claim 15 or claim 16.

Claim 18 (previously presented): A method for the detection/diagnosis of *S. pneumoniae* which comprises the step of bringing into contact a sample to be tested with at least one nucleic acid sequence as defined in claim 7 or claim 8.

Claim 19 (previously presented): A method of determining whether a protein or polypeptide as defined in Tables 2-4 represents a potential anti-microbial target which comprises inactivating said protein or polypeptide and determining whether *S. pneumoniae* is still viable *in vitro* or *in vivo*.

Claim 20 (currently amended): A method for treatment or prophylaxis of *S. pneumoniae* infection comprising administering to a patient in need thereof an agent capable of antagonizing, inhibiting or otherwise interfering with the function or expression of a protein or polypeptide as defined in Tables 2.4, wherein said agent induces an immune response in said patient to a polypeptide having a sequence comprising a polypeptide of SEQ. ID NO:162.

Claim 21 (currently amended): The method of claim 20, wherein the agent is a protein or polypeptide is formulated as a vaccine which comprises one or more additional components selected from excipients, diluents, adjuvants, or the like.

Claim 22 (previously presented): The method of claim 20 comprising administering a vaccine composition comprising one or more nucleic acid sequences encoding the amino acid sequence of SEQ ID NO:162 for prophylaxis or therapy of *S. pneumoniae* infection.